Infliximab is primarily used in the treatment of various autoimmune conditions. It is effective in managing moderate to severe rheumatoid arthritis, often in combination with methotrexate, to reduce symptoms and slow disease progression. It is also used for Crohn's disease, particularly in cases that do not respond to conventional therapies, helping to induce and maintain remission. Additionally, it is prescribed for ulcerative colitis to reduce inflammation and improve symptoms. Infliximab is also utilized in treating ankylosing spondylitis to alleviate pain and improve mobility. Furthermore, it is applied in psoriatic arthritis to reduce joint inflammation and skin lesions. Its ability to target and neutralize tumor necrosis factor-alpha (TNF-α) makes it a valuable therapeutic option in these conditions.